Skip to content

Member Log In
The Podcasts:
CME
The Rising Tide
NASH Tsunami

Menu

Member Log In
The Podcasts:
CME
The Rising Tide
NASH Tsunami

EASL 2021 Digital ILC

Grab Your Surf Board
& Join Us!

Livia Alimena
Naim Alkhouri
Michelle Long
Jörn Schattenberg
Roger Green
Louise Campbell
Manal Abdelmalek
Ken Cusi
Ian Rowe
Donna Cryer
Mazen Noureddin
Mike Charlton
Vlad Ratzui

Jump on board LIVE with our First Ever audience participation…

Thursday

June 24

7:00p CET, 1:00p EDT, 12:00n CDT

Friday

June 25

7:00p CET, 1:00p EDT, 12:00n CDT

Saturday

June 26

6:30p CET, 12:30p EDT, 11:30a CDT

Select the topics you are interested and we’ll send you a link to join the discussion LIVE!

Days/Times

Thursday June 24 – 7:00p CET, 1:00p EDT, 12:00n CDT Friday June 25 – 7:00p CET, 1:00p EDT, 12:00n CDT Saturday June 26 – 6:30p CET, 12:30p EDT, 11:30a CDT

First Name

Last Name

Email

Phone

Interested Topics/Abstracts

All-Thursday COVID-19 and the liver -- vaccination, variants and continuity of care AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints Incidence rates of select outcomes among patients with NASH and evidence of fibrosis or cirrhosis Life expectancy and risk of cardiovascular disease in non-alcoholic fatty liver disease: a population-based cohort study Lean NAFLD from the General French Population have more Severe Liver Disease and Poorer Clinical Outcomes (NASH-CO-study) All Friday Improving outcomes in liver disease: the role of primary care physicians Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD) - A Secondary Analysis of Two Randomized Controlled Trials Treatment of NAFLD with intermittent calorie restriction, low-carb high-fat diet or standard dietary advice - a randomized controlled trial. All Saturday Comparative diagnostic accuracy of blood-based biomarkers for staging fibrosis in NAFLD: phase 1 results of the LITMUS project Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with non-alcoholic fatty liver disease Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial Efruxifermin (EFX) improved markers of fibrosis, liver injury and metabolism in F4 NASH patients with compensated cirrhosis Elderly with advanced liver fibrosis had lower response to Pfizer's SARS-CoV-2 vaccine response

Listen Now

Apple Spotify Youtube

Copyright © SurfingNASH.Com 2020—2023

Linkedin Facebook Twitter Instagram

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Apple Spotify Youtube Soundcloud

Member Log In
Sponsorships
- Our Sponsors & Affiliates
- Sponsorship Programs
Surfers
Contact

Menu

Member Log In
Sponsorships
- Our Sponsors & Affiliates
- Sponsorship Programs
Surfers
Contact

June 1, 2023

S4-24 – Reviewing the 2023 Innovations in NAFLD Care Workshop

May 31, 2023

S4-23.4 – Deep Dive into Hepatocellular Ballooning and the Power of AI

May 31, 2023

S4-23.3 – Lowering Screen Fail Rates and Guidelines for the Biopsy Reading Process

May 31, 2023

S4-23.2 – The Future of AI-Assisted Digital Pathology and NITs

May 31, 2023

S4-23.1 – Obeticholic Acid: Is the Juice Worth the Squeeze?

May 24, 2023

S4-23 – Stephen Harrison on Challenges and Opportunities in NASH Drug Development

May 22, 2023

S4-22 – PART 1: FDA ADCOM Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

May 21, 2023

S4-21.5 – From the Vault: ILC 2022 Looking Back: NASH Is a Complex Disease

May 21, 2023

S4-21.4 – Previewing EASL Congress 2023: Virtual Attendance and the Power of Posters

May 20, 2023

S4-21.3 – Curating the EASL Congress 2023 Program and 3 “Can’t Miss” Features

Member Log In
The Podcasts:
CME
The Rising Tide
NASH Tsunami

Member Log In
Sponsorships
- Our Sponsors & Affiliates
- Sponsorship Programs
Surfers
Contact

Apple Spotify Youtube

Experience Nudge Learning! Interested in a new way of learning?

Learn More About CME